Skip to main content
  • Zydus Cadila receives tentative approval from USFDA for Osimertinib Tablets

    Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

  • One-dose Janssen COVID-19 vaccine approved by the MHRA

    The COVID-19 Vaccine Janssen has been given regulatory approval by the Medicines and Healthcare products Regulatory Agency . This is the fourth COVID-19 vaccine to be authorised by the UKs independent regulator and is the first to be approved for protection against COVID-19 with a single dose.

  • Bal Pharma Ltd launch of Favipiravir formulation into Indian market, under the brand name BALflu

    Bal Pharma Ltd is pleased to announce the launch of Favipiravir formulation into Indian market, under the brand name BALflu.

  • Roche Tecentriq helps certain people with early lung cancer live

    Roche announced interim results from the Phase III IMpower010 study, showing for the first time that treatment with Tecentriq (atezolizumab) following surgery and chemotherapy reduced the risk of disease recurrence or death (disease-free survival; DFS) by 34% (hazard ratio [HR]=0.66, 95% CI: 0.50–0.88) in people with Stage II-IIIA non-small cell lung cancer (NSCLC), whose tumours express PD-L1≥1%, compared with best supportive care (BSC). In this population, median DFS was not yet reached for Tecentriq compared with 35.3 months for BSC.

  • Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY

    Pfizer Inc. announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY, the companies COVID-19 vaccine, to the European Union (EU), with an option for the EC to request up to an additional 900 million doses.

  • Takeda announced Mobocertinib orally administered in patients with epidermal growth factor receptor

    Takeda Pharmaceutical Company Limited announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mNSCLC) who received prior platinum-based chemotherapy. The results showed mobocertinib continued to demonstrate clinically meaningful benefit after over a year of follow up and will be presented at the virtual 57th American Society of Clinical Oncology (ASCO) Annual Meeting on June 4.

  • Shilpa Medicare Limited ties up with Dr. Reddys Laboratories Limited for production of Sputnik V vaccine

    Shilpa Biologicals Private Limited, SBPL, has entered into a 3 year DefInitive Agreement with Dr. Reddys Laboratories Limited, DRL, for production supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka.

  • Dr. Reddys Laboratories enters into a Voluntary Licensing Agreement with Lilly to Expand Access toCOVID-19 Treatment in India

    Dr. Reddys Laboratories Ltd announced that it has entered into a royalty-free, non-exclusive voluntary  licensing agreement with  Eli Lilly and Company for the manufacture and commercialization of the drug, baricitinib,in India.

  • Dr. Reddys Laboratories announces the launch of Ertapenem for Injection in the U.S. Market

    Dr. Reddys Laboratories Ltd announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the U.S. Food and Drug Administration (USFDA).

  • BioArctic receives patent in Japan for new antibodies targeting Alzheimers disease

    BioArctic AB announced today that the Japanese Patent Office (JPO) has allowed the company’s Japanese patent application 2017-083057 for novel antibodies that could be developed into a treatment for Alzheimers disease. The antibodies target a shorter (truncated) form of amyloid beta (pE3-Aβ) and are linked to the company’s project AD1503. BioArctic received a patent in Europe based on the same antibodies in January 2021.

Subscribe to Company News

Search this website